Inventor · disambiguated record
Stephen Horrigan
Also filed as: HORRIGAN STEPHEN · HORRIGAN STEPHEN K
4 granted patents·16 pending applications·4 citations·filing 2001–2025
63Inventor score
Files withITERION THERAPEUTICS INC4AVALON PHARMACEUTICALS3YOUNG PAUL E2AUGUSTUS MEENA1BETA CAT PHARMACEUTICALS INC1
Top patents by PatentIndex Score
20 records- 0179US11266637B2Formulations of tegavivint and related compoundsITERION THERAPEUTICS INC·Filed 2019·Granted Mar 8, 2022·3 cites·11 claims
- 0272US11298346B2Methods for treatment of fibrotic diseasesBETA CAT PHARMACEUTICALS INC·Filed 2018·Granted Apr 12, 2022·1 cites·6 claims
- 0371US12246010B2Formulations of tegavivint and related compoundsITERION THERAPEUTICS INC·Filed 2022·Granted Mar 11, 2025·0 cites·15 claims
- 0466US2025205212A1Formulations of tegavivint and related compoundsITERION THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0560US2008050379A1Cancer gene determination and therapeutic screening using signature gene setsYOUNG PAUL E·Filed 2007·Application pending·0 cites
- 0659US2023012615A1Methods for treatment of fibrotic diseasesITERION THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0750US2005064454A1Cancer gene determination and therapeutic screening using signature gene setsFiled 2004·Application pending·0 cites
- 0849US2005287147A1Cancer-linked gene as target for chemotherapyEBNER REINHARD·Filed 2003·Application pending·0 cites
- 0949US2008025981A1Cancer-linked genes as targets for chemotherapyYOUNG PAUL E·Filed 2006·Application pending·0 cites
- 1048US2003219799A1Cancer-linked gene as target for chemotherapyFiled 2003·Application pending·0 cites
- 1148US2007270504A1Identification of Therapeutic Agents Using Genetic FingerprintingAVALON PHARMACEUTICALS·Filed 2004·Application pending·0 cites
- 1246US2022047528A1Methods of inhibiting lysine-specific demethylase 1 (lsd-1)SALARIUS PHARMACEUTICALS LLC·Filed 2021·Application pending·0 cites
- 1346US2010093611A1Compounds and methods for treating or preventing autoimmune diseasesHORRIGAN STEPHEN K·Filed 2008·Application pending·0 cites
- 1445US2004072192A1Cancer-linked genes as targets for chemotherapyFiled 2001·Application pending·0 cites
- 1541US2013123281A1Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated MoleculesVANKAYALAPATI HARIPRASAD M·Filed 2012·Application pending·0 cites
- 1641US2006134622A1Amplified cancer target genes useful in diagnosis and thereapeutic screeningAUGUSTUS MEENA·Filed 2003·Application pending·0 cites
- 1740US2009192046A1Chemo-selective identification of therapeuticsSOPPET DANIEL R·Filed 2007·Application pending·0 cites
- 1840US2007059697A1Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methodsAVALON PHARMACEUTICALS·Filed 2004·Application pending·0 cites
- 1938US9238030B2Methods for treatment of diseases and disorders related to transducin β-like protein 1 (TBL1) activity, including myeloproliferative neoplasia and chronic myeloid leukemiaBETA CAT PHARMACEUTICALS LLC·Filed 2012·Granted Jan 19, 2016·0 cites·20 claims
- 2037US2008305493A1Determining Cancer-Linked Genes and Therapeutic Targets Using Molecular Cytogenetic MethodsAVALON PHARMACEUTICALS·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stephen Horrigan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →